Back

REACT-1 round 9 final report: Continued but slowing decline of prevalence of SARS-CoV-2 during national lockdown in England in February 2021

Riley, S.; Walters, C. E.; Wang, H.; Eales, O.; Haw, D.; Ainslie, K. E. C.; Atchinson, C.; Fronterre, C.; Diggle, P. J.; Ashby, D.; Donnelly, C. A.; Cooke, G.; Barclay, W.; Ward, H.; Darzi, A.; Elliott, P.

2021-03-06 infectious diseases
10.1101/2021.03.03.21252856 medRxiv
Show abstract

BackgroundEngland will start to exit its third national lockdown in response to the COVID-19 pandemic on 8th March 2021, with safe effective vaccines being rolled out rapidly against a background of emerging transmissible and immunologically novel variants of SARS-CoV-2. A subsequent increase in community prevalence of infection could delay further relaxation of lockdown if vaccine uptake and efficacy are not sufficiently high to prevent increased pressure on healthcare services. MethodsThe PCR self-swab arm of the REal-time Assessment of Community Transmission Study (REACT-1) estimates community prevalence of SARS-CoV-2 infection in England based on random cross-sections of the population ages five and over. Here, we present results from the complete round 9 of REACT-1 comprising round 9a in which swabs were collected from 4th to 12th February 2021 and round 9b from 13th to 23rd February 2021. We also compare the results of REACT-1 round 9 to round 8, in which swabs were collected mainly from 6th January to 22nd January 2021. ResultsOut of 165,456 results for round 9 overall, 689 were positive. Overall weighted prevalence of infection in the community in England was 0.49% (0.44%, 0.55%), representing a fall of over two thirds from round 8. However the rate of decline of the epidemic has slowed from 15 (13, 17) days, estimated for the period from the end of round 8 to the start of round 9, to 31 days estimated using data from round 9 alone (lower confidence limit 17 days). When comparing round 9a to 9b there were apparent falls in four regions, no apparent change in one region and apparent rises in four regions, including London where there was a suggestion of sub-regional heterogeneity in growth and decline. Smoothed prevalence maps suggest large contiguous areas of growth and decline that do not align with administrative regions. Prevalence fell by 50% or more across all age groups in round 9 compared to round 8, with prevalence (round 9) ranging from 0.21% in those aged 65 and over to 0.71% in those aged 13 to 17 years. Round 9 prevalence was highest among Pakistani participants at 2.1% compared to white participants at 0.45% and Black participants at 0.83%. There were higher adjusted odds of infection for healthcare and care home workers, for those working in public transport and those working in education, school, nursery or childcare and lower adjusted odds for those not required to work outside the home. ConclusionsCommunity prevalence of swab-positivity has declined markedly between January and February 2021 during lockdown in England, but remains high; the rate of decline has slowed in the most recent period, with a suggestion of pockets of growth. Continued adherence to social distancing and public health measures is required so that infection rates fall to much lower levels. This will help to ensure that the benefits of the vaccination roll-out programme in England are fully realised.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
The Lancet Infectious Diseases
71 papers in training set
Top 0.2%
9.9%
2
BMJ Open
554 papers in training set
Top 2%
8.2%
3
Journal of Infection
71 papers in training set
Top 0.1%
7.0%
4
Nature Communications
4913 papers in training set
Top 27%
6.7%
5
Emerging Infectious Diseases
103 papers in training set
Top 0.3%
6.2%
6
Wellcome Open Research
57 papers in training set
Top 0.2%
4.7%
7
The Lancet Regional Health - Europe
32 papers in training set
Top 0.1%
4.2%
8
Eurosurveillance
80 papers in training set
Top 0.2%
4.2%
50% of probability mass above
9
PLOS Medicine
98 papers in training set
Top 0.9%
3.9%
10
BMC Infectious Diseases
118 papers in training set
Top 1%
3.5%
11
The Lancet
16 papers in training set
Top 0.1%
3.5%
12
Science
429 papers in training set
Top 9%
3.5%
13
eClinicalMedicine
55 papers in training set
Top 0.2%
2.8%
14
PLOS ONE
4510 papers in training set
Top 49%
2.0%
15
BMJ
49 papers in training set
Top 0.5%
2.0%
16
International Journal of Epidemiology
74 papers in training set
Top 1%
2.0%
17
BMC Medicine
163 papers in training set
Top 3%
2.0%
18
BMC Public Health
147 papers in training set
Top 4%
1.6%
19
The Lancet Public Health
20 papers in training set
Top 0.3%
1.5%
20
Clinical Infectious Diseases
231 papers in training set
Top 3%
1.3%
21
Epidemiology and Infection
84 papers in training set
Top 2%
1.3%
22
Thorax
32 papers in training set
Top 0.6%
1.2%
23
The Lancet Healthy Longevity
11 papers in training set
Top 0.1%
0.9%
24
International Journal of Infectious Diseases
126 papers in training set
Top 3%
0.9%
25
Journal of Epidemiology and Community Health
32 papers in training set
Top 0.5%
0.9%
26
JAMA Network Open
127 papers in training set
Top 4%
0.9%
27
New England Journal of Medicine
50 papers in training set
Top 0.8%
0.8%
28
The Lancet Respiratory Medicine
17 papers in training set
Top 0.3%
0.7%
29
Open Forum Infectious Diseases
134 papers in training set
Top 3%
0.6%
30
The Lancet Global Health
24 papers in training set
Top 1%
0.6%